Regeneron Pharmaceuticals stock rose nearly 5% after impressive Q4 results and positive guidance for 2025.

From Nasdaq: 2025-02-04 18:44:42

Regeneron Pharmaceuticals (NASDAQ: REGN) saw a nearly 5% share price gain after posting impressive fourth-quarter and full-year 2024 results. Revenue grew by 10% to $3.79 billion, with adjusted net income rising 2% to $1.39 billion. Eylea sales increased by 2% to nearly $1.5 billion, while cancer drug Libtayo sales jumped 50% to $367 million. The company’s collaboration revenue also rose by 17% to $1.61 billion. Regeneron provided guidance for 2025, expecting to spend $5-5.2 billion on R&D and $850-975 million on capital expenditures. Despite not giving revenue forecasts, it was a solid earnings report overall.

Considerations for investing in Regeneron Pharmaceuticals: The Motley Fool’s analyst team did not include Regeneron in their list of the 10 best stocks to buy now. The Stock Advisor service, with a strong track record since 2002, provides guidance on building a portfolio and offers two new stock picks each month. While Regeneron has shown positive growth and potential, investors may want to explore other options for potentially higher returns based on historical performance.



Read more at Nasdaq: Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday